131 related articles for article (PubMed ID: 15989575)
1. Anticancer activity of farnesyltransferase and geranylgeranyltransferase I inhibitors: prospects for drug development.
Sebti SM; Hamilton AD
Expert Opin Investig Drugs; 1997 Nov; 6(11):1711-4. PubMed ID: 15989575
[TBL] [Abstract][Full Text] [Related]
2. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues.
Sebti SM; Hamilton AD
Expert Opin Investig Drugs; 2000 Dec; 9(12):2767-82. PubMed ID: 11093352
[TBL] [Abstract][Full Text] [Related]
3. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
4. [Inhibitors of isoprenylation of ras p21].
Yoshimatsu K
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1495-502. PubMed ID: 9309147
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
[TBL] [Abstract][Full Text] [Related]
6. Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer.
Liu M; Sjogren AK; Karlsson C; Ibrahim MX; Andersson KM; Olofsson FJ; Wahlstrom AM; Dalin M; Yu H; Chen Z; Yang SH; Young SG; Bergo MO
Proc Natl Acad Sci U S A; 2010 Apr; 107(14):6471-6. PubMed ID: 20308544
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting the "Undruggable" RAS/Farnesyltransferase (FTase) Cancer Target by Manumycin-related Natural Products.
Silva LR; da Silva-JĂșnior EF
Curr Med Chem; 2022; 29(2):189-211. PubMed ID: 33719954
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of farnesyltransferase and geranylgeranyltransferase I by caspase-3: cleavage of the common alpha subunit during apoptosis.
Kim KW; Chung HH; Chung CW; Kim IK; Miura M; Wang S; Zhu H; Moon KD; Rha GB; Park JH; Jo DG; Woo HN; Song YH; Kim BJ; Yuan J; Jung YK
Oncogene; 2001 Jan; 20(3):358-66. PubMed ID: 11313965
[TBL] [Abstract][Full Text] [Related]
9. Theoretical studies on binding and specificity mechanisms of farnesyltransferase (FTase) and geranylgeranyltransferase type-I (GGTase-I) inhibitors by molecular modeling.
Zhou S
Comb Chem High Throughput Screen; 2014; 17(6):509-19. PubMed ID: 24444014
[TBL] [Abstract][Full Text] [Related]
10. Farnesyltransferase and geranylgeranyltransferase I: structures, mechanism, inhibitors and molecular modeling.
Shen M; Pan P; Li Y; Li D; Yu H; Hou T
Drug Discov Today; 2015 Feb; 20(2):267-76. PubMed ID: 25450772
[TBL] [Abstract][Full Text] [Related]
11. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.
Rowinsky EK; Windle JJ; Von Hoff DD
J Clin Oncol; 1999 Nov; 17(11):3631-52. PubMed ID: 10550163
[TBL] [Abstract][Full Text] [Related]
12. Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem.
Sousa SF; Fernandes PA; Ramos MJ
Curr Med Chem; 2008; 15(15):1478-92. PubMed ID: 18537624
[TBL] [Abstract][Full Text] [Related]
13. Upstream polybasic region in peptides enhances dual specificity for prenylation by both farnesyltransferase and geranylgeranyltransferase type I.
Hicks KA; Hartman HL; Fierke CA
Biochemistry; 2005 Nov; 44(46):15325-33. PubMed ID: 16285736
[TBL] [Abstract][Full Text] [Related]
14. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
Sun J; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
[TBL] [Abstract][Full Text] [Related]
15. A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors.
Del Villar K; Urano J; Guo L; Tamanoi F
J Biol Chem; 1999 Sep; 274(38):27010-7. PubMed ID: 10480914
[TBL] [Abstract][Full Text] [Related]
16. Recent progress in developing small molecule inhibitors designed to interfere with ras membrane association: toward inhibiting K-Ras and N-Ras functions.
Tamanoi F; Lu J
Enzymes; 2013; 34 Pt. B():181-200. PubMed ID: 25034105
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors.
Qian Y; Vogt A; Sebti SM; Hamilton AD
J Med Chem; 1996 Jan; 39(1):217-23. PubMed ID: 8568811
[TBL] [Abstract][Full Text] [Related]
18. Crystallographic analysis reveals that anticancer clinical candidate L-778,123 inhibits protein farnesyltransferase and geranylgeranyltransferase-I by different binding modes.
Reid TS; Long SB; Beese LS
Biochemistry; 2004 Jul; 43(28):9000-8. PubMed ID: 15248757
[TBL] [Abstract][Full Text] [Related]
19. J-104,871, a novel farnesyltransferase inhibitor, blocks Ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner.
Yonemoto M; Satoh T; Arakawa H; Suzuki-Takahashi I; Monden Y; Kodera T; Tanaka K; Aoyama T; Iwasawa Y; Kamei T; Nishimura S; Tomimoto K
Mol Pharmacol; 1998 Jul; 54(1):1-7. PubMed ID: 9658183
[TBL] [Abstract][Full Text] [Related]
20. Geranylgeranyltransferase I as a target for anti-cancer drugs.
Philips MR; Cox AD
J Clin Invest; 2007 May; 117(5):1223-5. PubMed ID: 17476354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]